Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | GAPDH | P04406 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | STAT6 | P42226 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22855710 | 0.91 | AHCY (0.50) | AHCYADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL23547678 | 0.91 | ADORA3 (0.56) | AHCYADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL21998899 | 0.90 | ADORA1 (0.57) | AHCYADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL22855775 | 0.89 | ADORA1 (0.52) | ADORA3ADORA1ADORA2AADORA2BGAA | |
| SCHEMBL12590110 | 0.89 | ADORA1 (0.52) | ADORA3ADORA1ADORA2AADORA2BGAA | |
| SCHEMBL12646696 | 0.89 | ADORA1 (0.52) | ADORA3ADORA1ADORA2AADORA2BGAA | |
| SCHEMBL12015179 | 0.89 | ADORA1 (0.52) | ADORA3ADORA1ADORA2AADORA2BGAA | |
| SCHEMBL12376385 | 0.88 | ADORA3 (0.56) | AHCYADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL21999054 | 0.88 | ADORA3 (0.56) | AHCYADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL12360836 | 0.88 | ADORA3 (0.56) | AHCYADORA3ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125825-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-11166976-B2 | S-antigen transport inhibiting oligonucleotide polymers and methods | ALIGOS THERAPEUTICS, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200405743-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166976-B2 | S-antigen transport inhibiting oligonucleotide polymers and methods | RNGTT, PHAX, HAVCR2 | AHCY 532/4885ADORA3 1372/4885ADORA1 1419/4885 |
| US-20200405743-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | RNGTT, PHAX, HAVCR2 | AHCY 532/4885ADORA3 1372/4885ADORA1 1419/4885 |
| US-20220125825-A1 | S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS AND METHODS | RNGTT, PHAX, HAVCR2 | AHCY 532/4885ADORA3 1372/4885ADORA1 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.